93: Outcome with a thiotepa containing regimen and autologous HSCT in patients with NHL
Aaron Cumpston(West Virginia University Hospitals), Solveig G. Ericson, Nathan Visweshwar(University of South Florida), Abraham S. Kanate(HonorHealth), Deirdre Bulian(West Virginia University), Michael Craig(Edith Cowan University), Pamela Bunner(West Virginia University), Robin Weisenborn(West Virginia University Hospitals)
Cited by 1
Related Papers
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2020|278
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
|Blood|2015|273
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
|Blood|2017|247
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183